ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.
More...
More...